Canaccord analyst David Hynes lowered the firm’s price target on Definitive Healthcare (DH) to $4 from $5 and keeps a Hold rating on the shares. The firm said the positive takeaways here are that new customer acquisition exceeded internal expectations, the firm is making progress on mitigating downsell pressures, and gross revenue retention should be up year-over-year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare Earnings Call: Mixed Sentiment Amid Challenges
- Definitive Healthcare Corp: Solid Q3 Results Amidst Retention Challenges Justify Hold Rating
- Definitive Healthcare price target lowered to $5 from $6 at Stifel
- Definitive Healthcare price target lowered to $3 from $4 at Baird
- Definitive Healthcare Corp. Reports Q3 2025 Results